Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + radiotherapy
- Development stage
- Unknown
- Lead developer
- Biocon
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Radiation
01
Overview
Nimotuzumab + radiotherapy is a combination therapy regimen used to treat various cancers. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). EGFR is overexpressed in many types of cancer and plays a role in cell growth, survival, and angiogenesis. By binding to EGFR, nimotuzumab inhibits downstream signaling pathways. Radiotherapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. The combination of nimotuzumab and radiotherapy is based on the rationale that EGFR signaling can contribute to radioresistance. Inhibiting EGFR with nimotuzumab aims to enhance the cytotoxic effects of radiation and improve treatment outcomes.
- Brand names
- TheraCIMBIOMAb EGFR
- Other names
- nimotuzumab plus radiotherapynimotuzumab combined with
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on nimotuzumab + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + radiotherapy.